Comparative Pharmacology
Head-to-head clinical analysis: BEOVU versus PYZCHIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEOVU versus PYZCHIVA.
BEOVU vs PYZCHIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brolucizumab is a humanized monoclonal antibody Fab fragment that inhibits vascular endothelial growth factor (VEGF)-A, preventing its binding to VEGFR-1 and VEGFR-2 receptors, thereby reducing endothelial cell proliferation, neovascularization, and vascular permeability.
Biosimilar to infliximab; a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), neutralizing its activity and reducing inflammation.
0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once every 4 weeks (monthly) for 12 months, then may be extended to once every 8 weeks (every 2 months) based on clinical response.
Intravenous infusion of 300 mg over 60 minutes on days 1, 15, and 29, then every 4 weeks thereafter.
None Documented
None Documented
Terminal half-life approximately 26 days (range 23-31 days) in patients with neovascular age-related macular degeneration, supporting monthly intravitreal dosing.
Terminal elimination half-life approximately 21-25 days (mean 23 days), consistent with IgG1 monoclonal antibody clearance; supports monthly dosing.
Primarily metabolic clearance; <1% excreted unchanged in urine. Biliary/fecal excretion not characterized for parent drug.
Primarily eliminated via the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor